23andMe Inc.

Company Overview

23andMe is a pioneer in direct-to-consumer genetic testing. It is the first company to receive FDA authorization for a direct-to-consumer genetic test. Also, it is the only company possessing FDA clearance or exemption from premarket notification for every carrier status, genetic health risk, cancer predisposition and pharmacogenetics report it provides to its end users. The company operates in two business segments- Consumer & Research Services and Therapeutics.

The company caters to the direct-to-consumer testing market through the Consumer & Research Services segment. This segment is divided into Personal Genome Services (“PGS”), telehealth business and research services. PGS services provide end users with a comprehensive array of genetic reports, encompassing details about their genetic ancestral roots, individual genetic health risks, the probability of transmitting specific rare carrier conditions to children and insights into how genetics influence responses to medication.

The company has about 60 health and carrier status reports accessible to customers in the U.S. as of March 2023. Additionally, in the U.S., Canada and the U.K., the company presents two PGS services and a premium subscription service known as 23andMe+. The company's Ancestry Service and Health + Ancestry Service can be accessed on both 23andMe.com and the mobile app. Furthermore, the Health Service is available for purchase on Amazon and fsastore.com.

Financial Highlights (FY 2023)

Company's Business Segments

• Consumer Services : Personal Genome Service, Telehealth Business, DNA Testing, Genetic Ancestral Origins Services.
• Research services : Through Research Services, company use their vast Database of Genetic and Phenotypic information provided by consenting customers to discover insights into the Genetic Origins of disease and to identify and validate targets for Drug Development.